PARP Inhibition for Ovarian Cancer - prIME Oncology
Expert Review
Expert Review

PARP Inhibition for Ovarian Cancer

Incorporating New Clinical Findings

View Activity

Not a member of My prIME? Join now for instant access.

The information in this activity is intended for healthcare professionals based outside of the United States. This activity may contain information on products outside the approved indications where you practice.

This Expert Review features a discussion and downloadable slides focusing on the role of PARP inhibition in ovarian cancer, including mechanism of action and biomarkers for treatment, emerging clinical data, and patient selection for treatment.

Interactive Presentation

Interactive Presentation

Downloadable Slides

Downloadable Slides



Release Date

Release Date

Jun 29, 2017

Expiration Date

Jun 30, 2018


  • Robert Coleman, MD, FRCP, FRCPEMedical Director, prIME Oncology
    University of Sheffield
    Weston Park Hospital
    Sheffield, United Kingdom
  • Amit Oza, MD, FRCPC, MBBSPrincess Margaret Hospital
    University of Toronto
    Toronto, Ontario, Canada
  • Eric Pujade-Lauraine, MD, PhDCentre Hospitalier Universitaire Hôtel-Dieu
    Paris, France
  • Ovarian cancer and defects in DNA repair mechanisms
  • PARP inhibitors: Mechanism of action
  • Clinical data on PARP inhibitors in ovarian cancer
  • Patient selection for PARP inhibitors
  • Future directions in PARP inhibitors for ovarian cancer

This educational activity is specifically designed for gynecologic oncologists, medical oncologists, and other healthcare providers involved in the management of patients with advanced ovarian cancer.

After successful completion of this educational activity, participants should be able to:

  • Describe the mechanism of action of PARP inhibitors and identify predictive biomarkers of sensitivity to these agents
  • Assess emerging clinical data and ongoing trials involving PARP inhibitors in both BRCA 1/2-mutant and BRCA 1/2-wildtype patients and across various treatment settings of ovarian cancer

This educational activity is supported by a grant from AstraZeneca.

Independent Medical Education (IME)

This IME activity is organized by prIME Oncology. This activity provides content that is evidence-based, balanced, and free of commercial bias, with a primary objective to improve competence and performance of learners in order to improve patient care.


This activity is provided by prIME Oncology.

Disclosure Information


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.